These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Exempt 2007-003211-31 ENSAYO CLÍNICO DE FASE I-II, NO ALEATORIZADO, MULTICENTRICO PARA EVALUAR LA SEGURIDAD Y LA EFICACIA DE LA COMBINACIÓN DE SORAFENIB (BAY 43-9006), GEMCITABINA Y RADIOTERAPIA CONCURRENTE EN EL TRATAMIE... not-yet-due
Ongoing 2008-004223-27 Estudio fase II, de la combinación de Oxaliplatino y Sorafenib en pacientes con Adenocarcinoma gástrico o de la unión gastroesofágica localmente avanzado o metastásico, en progresión tras un esquema ... not-yet-due
Ongoing 2009-010417-73 Estudio abierto, no aleatorizado, multicéntrico, en fase II, para evaluar la eficacia y seguridad de Bevacizumab en combinación con Capecitabina y Oxaliplatino, como primera línea de tratamiento en pa... not-yet-due
Completed, but no date 2009-017331-18 Estudio abierto de fase II para evaluar los posibles marcadores tumorales predictivos en pacientes con cáncer colorrectal metastásico y tumor con KRAS no mutado tratados con FOLFOX6m y panitumumab com... bad-data
Completed, but no date, and reported results 2010-018430-48 Estudio de fase II para evaluar la eficacia y la seguridad de la quimiorradioterapia con 5-fluorouracilo, mitomicina C y panitumumab como tratamiento del carcinoma anal de células escamosas bad-data
Completed, but no date, and reported results 2010-019236-12 Ensayo clínico fase II de un solo brazo, multicéntrico y prospectivo para la validación de biomarcadores en pacientes con cáncer colorrectal avanzado y/o metastásico con gen KRAS no mutado tratados co... bad-data
Ongoing 2010-021738-72 Estudio fase II abierto, no aleatorizado, para evaluar la eficacia y seguridad del tratamiento neoadyuvante concomitante de Gemcitabina y Erlotinib seguido de Gemcitabina, Erlotinib y radioterapia en ... not-yet-due
Reported results 2011-000143-24 Phase IV, multicentric study to evaluate correlation between global objectives response according RECIST v1.1 criteria evaluated by conventional images tecniques with morfologic response by TAC and pa... 2017-12-18 due-trials
Reported results 2014-002063-14 Induction FOLFOX with or without Aflibercept followed by chemoradiation in High Risk Locally Advanced Rectal Cancer. Phase II randomized, multicenter, open label trial Tratamiento de inducción con ... 2020-02-04 due-trials
Completed, but no date Terminated 2016-002333-29 Preoperative induction therapy with 12 weeks of Panitumumab in combination with mFOLFOX-6 in an enriched population (Quadruple Wild-Type) of patients with mrT3 rectal cancer of the middle third with c... bad-data
Exempt, with results 2016-003838-24 A single arm Phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. Ensayo Clínico ... not-yet-due
Ongoing, reported early 2017-001639-38 A phase II trial to evaluate the efficacy and safety of FOLFIRI + panitumumab as first-line treatment in elderly patients with RAS/BRAF wild-type unresectable metastatic colorectal cancer and good per... not-yet-due
Completed, but no date Terminated 2017-004519-38 Randomized phase II study to evaluate the efficacy of second-line FOLFIRI + panitumumab in subjects with wild type RAS metastatic colorectal cancer who have received FOLFOX + panitumumab in first-line... bad-data
Ongoing 2018-004835-56 Phase II study of Durvalumab (MEDI4736) plus Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer Estudio en fase II de Durvalumab (MEDI4736) más terapia total neoadyuvante en el cánc... not-yet-due
Ongoing 2021-003767-10 Phase II trial of Pembrolizumab and Olaparib in homologous-recombination deficient (HRD) advanced colorectal cancer (CRC). Ensayo de fase II de Pembrolizumab y Olaparib en cáncer colorrectal avanza... not-yet-due
Ongoing 2021-005887-24 Phase II study of Atezolizumab plus Tiraglolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal Tiraglolumab más Atezolizumab en combinación con quimio... not-yet-due